(Q53155413)

English

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.

scientific article published on 30 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. (English)

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Efstathios Kastritis

4

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Athanasios Dimopoulos

18

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Eurydiki Michalis

8

object named as

Eurydiki Michalis

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Maria Gkotzamanidou

10

object named as

Maria Gkotzamanidou

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Evangelos Terpos

1

object named as

Evangelos Terpos

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Ekaterini Stefanoudaki

15

object named as

Ekaterini Stefanoudaki

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Dimitrios Christoulas

6

object named as

Dimitrios Christoulas

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Konstantinos Anargyrou

2

object named as

Konstantinos Anargyrou

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Eirini Katodritou

3

object named as

Eirini Katodritou

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Anastasia Pouli

7

object named as

Anastasia Pouli

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Konstantinos Tsionos

14

object named as

Konstantinos Tsionos

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Sosana Delimpasi

9

object named as

Sosana Delimpasi

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

16

object named as

John Meletis

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Athanasios Papatheodorou

5

object named as

Athanasios Papatheodorou

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

author name string

Nikitas Nikitas

11

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Vasilios Koumoustiotis

12

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Dimitrios Margaritis

13

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Konstantinos Zervas

17

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Greek Myeloma Study Group, Greece

19

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

language of work or name

0 references

publication date

30 May 2011

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

International Journal of Cancer

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

130

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

3

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

735-742

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

Novel anti-myeloma agents and angiogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Clinician guide to angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Individualizing treatment of patients with myeloma in the era of novel agents.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Anti-angiogenic effect of bortezomib in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26062

21 January 2018

Identifiers

10.1002/IJC.26062

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/21484787

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53155413&oldid=1744575470"